Figure 5. PARP1 inhibitor rucaparib reversed oxaliplatin-induced parthanatos in OSCC cells. CAL27 and SCC25 cells were treated with or without oxaliplatin or oxaliplatin plus rucaparib. (A, B) The cell death ratio based on LDH release assay of CAL27 and SCC25 cells. (C, D) The protein levels of PARP1, AIF and MIF in the nucleus and cytoplasm of CAL27 cells. (E, F) Representative images of AIF immunofluorescence staining in CAL27 and SCC25 cells. Arrows indicates typical cells with AIF nuclear translocation. * p<0.05, **p<0.01.